Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. COVID-19 generated by SARS-CoV-2 infection may cause mild, moderate, or severe illness; the latter includes severe pneumonia, ARF, ARDS, AKI, endothelial damage, coagulopathy, sepsis and septic shock.
As in sepsis, endotoxemia can be found in the blood of patients with COVID-19 pneumonia, indicating that loss of intestinal barrier function significantly contributes to the pathogenesis of COVID-19.
Patients who are hospitalized for extended periods in an ICU are more prone to superimposed infections.
Gram-negative infection and/or direct mucosal gut translocation lead to the circulation of endotoxin (endotoxemia).
During this webinar we discuss the pathophysiology of septic shock and COVID-19, the role of endotoxemia and rationale of Polymyxin B hemoperfusion in specific populations.
Data on Polymyxin B hemoperfusion use in Endotoxic Shock patients will be presented including COVID-19 patients, discussing the complementary role of EUPHAS 2 registry in addition to RCT studies.
Finally, we will talk about sepsis-induced AKI, the importance of dialysis membrane as therapeutic choice and the new approach of sequential therapies in sepsis treatment.
ORGANIZING SECRETARIAT
Start Promotion Eventi S.r.l.
Via Mauro Macchi, 50
20124 Milano - Italy
Tel. +39 02 67071383
Fax +39 02 67072294
www.startpromotioneventi.it
info@startpromotioneventi.it
Please refer to:
vera.tavella@startpromotioneventi.it